Stryker Corp Q2 2022 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Maybe I'd start on second half. It's sort of like a tale of 2 cities where you have this really strong top line and somewhat of a pressured bottom line. And moving organic sales guidance up 100 basis points is great to see. But it does look like roughly 2/3 of EPS down move is currency, a little bit from operations. So maybe just walk us through -- it sounds like medical is going to get a good chunk better in the second half. Maybe just give us a little color of how you get the confidence to raise the top line and where exactly you're seeing the softening operating margin constant currency.

Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst : Great. Maybe as a quick follow-up, Kevin or Glenn. I'm getting a little greedy here, but I'm already looking out to next year. And we've heard from a number of companies that have reported so far to use 2022 as a base year. Don't treat it as a onetime easy comp. And I look at sell-side numbers for next year, and it's about 100 basis points of operating margin expansion. So I know nobody is good enough to forecast next year yet. But do you have any early thoughts on 2023 margins? Are you committed to growing margins next year? And just if you have any color on your interpretation of the -- where the sell-side sits right now?